CORONA Remedies Q2 FY27 Results: Revenue at ₹714.41 Crore, Profit at ₹1339.37 Lakhs
CORONA Remedies reported Q2 FY27 results. Consolidated revenue was ₹714.41 crore, up 36.5% YoY, with profit after tax at ₹13.39 crore. Standalone revenue grew 44.5% to ₹690.53 crore, with profit after tax at ₹13.80 crore. Results published on Oct 31, 2026.
The announcement contains key financial performance indicators, including revenue and profit growth, which are material information for investors and stakeholders.
The company has reported significant year-on-year growth in revenue for both consolidated and standalone figures in the second quarter and half-year ended September 30, 2026.
CORONA Remedies Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The Board of Directors, in their meeting on October 30, 2026, approved these results.
The company reported consolidated revenue from operations of ₹714.41 crore for the second quarter ended September 30, 2026. This represents a growth of 36.5% compared to the same period in the previous year. The net profit after tax for the quarter stood at ₹13.39 crore.
For the half-year ended September 30, 2026, consolidated revenue from operations was ₹1,390.53 crore, a 4.3% increase year-on-year. The consolidated net profit after tax for the half-year was ₹5.51 crore.
On a standalone basis, revenue from operations for the second quarter ended September 30, 2026, was ₹690.53 crore, an increase of 44.5% year-on-year. The standalone net profit after tax for the quarter was ₹13.80 crore.
For the half-year ended September 30, 2026, standalone revenue from operations reached ₹1,381.06 crore, a 47.7% increase year-on-year. The standalone net profit after tax for the half-year was ₹5.59 crore.
The newspaper advertisement containing the unaudited financial results was published on October 31, 2026, in the Financial Express (English and Gujarati). These results are also available on the company's website.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.